DPP HIV-Syphilis receives CLIA Waiver: The First & Only FDA Approved, CLIA Waived* HIV-Syphilis Rapid Test
*CLIA Waived for fingerstick whole blood
Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK® Assay at Chembio Diagnostics Malaysia Facility
Launching Status™ COVID-19/Flu 15 Minute Visual Read Rapid Test in the USA
Launching DPP® SARS-CoV-2 Antigen System in Brazil
Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.
Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.
Our Core Values: “RAPID”
Chembio is a leading point of care diagnostics company focused on detecting and diagnosing infectious diseases.
Our patented DPP® technology platform uses a small drop of blood from the fingertip and provides high-quality, cost-effective results in 15-20 minutes. Our products are sold globally, directly and through distributors, to hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.